{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:18:54Z","timestamp":1776889134037,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2023-MS-170"],"award-info":[{"award-number":["2023-MS-170"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.gassur.2025.102307","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:08:32Z","timestamp":1766120912000},"page":"102307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy of immunotherapy in the treatment of tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5410-4083","authenticated-orcid":false,"given":"YuLong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XianHao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JiaYing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gassur.2025.102307_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2174\/15748928113089990030","article-title":"Biomarkers and novel therapeutic targets in gastrointestinal stromal tumors (GISTs)","volume":"8","author":"Campanella","year":"2013","journal-title":"Recent Pat Anticanc Drug Discov"},{"key":"10.1016\/j.gassur.2025.102307_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"S\u00f8reide","year":"2016","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"10.1016\/j.gassur.2025.102307_bib3","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/annonc\/mds587","article-title":"Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial","volume":"24","author":"Patrikidou","year":"2013","journal-title":"Ann Oncol"},{"issue":"9440","key":"10.1016\/j.gassur.2025.102307_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.gassur.2025.102307_bib5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41419-024-06571-3","article-title":"Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1073\/pnas.1009199108","article-title":"Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations","volume":"108","author":"Janeway","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.gassur.2025.102307_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health gastrointestinal stromal tumor clinic","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2025.102307_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10555-019-09818-0","article-title":"Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors","volume":"38","author":"Neppala","year":"2019","journal-title":"Cancer Metastas Rev"},{"issue":"7","key":"10.1016\/j.gassur.2025.102307_bib9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.gassur.2025.102307_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2016.71.0228","volume":"35","author":"Casali","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9544","key":"10.1016\/j.gassur.2025.102307_bib11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.gassur.2025.102307_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","article-title":"The management of metastatic GIST: current standard and investigational therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.gassur.2025.102307_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12943-023-01770-6","article-title":"Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.gassur.2025.102307_bib17","first-page":"3563","article-title":"Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST)","volume":"7","author":"Cameron","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"10.1016\/j.gassur.2025.102307_bib18","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","article-title":"Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors","volume":"73","author":"Rusakiewicz","year":"2013","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.gassur.2025.102307_bib19","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.gassur.2025.102307_bib20","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","article-title":"Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL\u2212 tumors","volume":"181","author":"Larmonier","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.gassur.2025.102307_bib22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"10.1016\/j.gassur.2025.102307_bib23","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.gassur.2025.102307_bib24","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.gassur.2025.102307_bib25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gassur.2025.102307_bib26","series-title":"JBI manual for evidence synthesis","author":"Aromataris","year":"2024"},{"issue":"7414","key":"10.1016\/j.gassur.2025.102307_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"issue":"11","key":"10.1016\/j.gassur.2025.102307_bib29","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.gassur.2025.102307_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.178","article-title":"Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives","volume":"3","author":"Lin","year":"2020","journal-title":"Health Sci Rep"},{"issue":"Sect E 1","key":"10.1016\/j.gassur.2025.102307_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/cjr48e-001","article-title":"Statistical methods in medical research; qualitative statistics, enumeration data","volume":"26","author":"Mainland","year":"1948","journal-title":"Can J Res"},{"key":"10.1016\/j.gassur.2025.102307_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2288-9-80","article-title":"Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data","volume":"9","author":"Wallace","year":"2009","journal-title":"BMC Med Res Method"},{"issue":"7109","key":"10.1016\/j.gassur.2025.102307_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.gassur.2025.102307_bib34","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.gassur.2025.102307_bib35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-011-1185-1","article-title":"Exploiting antitumor immunity to overcome relapse and improve remission duration","volume":"61","author":"Chen","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.gassur.2025.102307_bib36","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1158\/1078-0432.CCR-16-2349","article-title":"Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab","volume":"23","author":"D\u2019Angelo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gassur.2025.102307_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-017-0238-1","article-title":"Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies","volume":"5","author":"Reilley","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","article-title":"Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials","volume":"5","author":"Groisberg","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.gassur.2025.102307_bib40","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00262-020-02625-5","article-title":"Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors","volume":"69","author":"Fr\u00f6bom","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.gassur.2025.102307_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-21-0878","article-title":"A randomized Phase II study of nivolumab monotherapy or nivolumab combined with ipilimumab in patients with advanced gastrointestinal stromal tumors","volume":"28","author":"Singh","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.gassur.2025.102307_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009472","article-title":"A multicenter, randomized, non-comparative, phase II study of nivolumab +\/\u2212 ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses","volume":"12","author":"Seligson","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.gassur.2025.102307_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115565","article-title":"Avelumab plus axitinib in patients with advanced gastrointestinal stromal tumor","volume":"225","author":"Rutkowski","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.gassur.2025.102307_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.789915","article-title":"Clinical and prognostic significance of tumor-infiltrating CD8+ T cells and PD-L1 expression in primary gastrointestinal stromal tumors","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2025.102307_bib45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.molimm.2008.10.007","article-title":"The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective","volume":"46","author":"Hansen","year":"2009","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1016\/j.gassur.2025.102307_bib46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.gassur.2025.102307_bib47","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432234","article-title":"Immunotherapy in sarcoma: current data and promising strategies","volume":"44","author":"Wood","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.gassur.2025.102307_bib48","article-title":"Immune infiltration, cancer stemness, and targeted therapy in gastrointestinal stromal tumor","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.gassur.2025.102307_bib49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/cgt.2016.58","article-title":"Current status of immunotherapy for gastrointestinal stromal tumor","volume":"24","author":"Tan","year":"2017","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.gassur.2025.102307_bib50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.humpath.2017.01.005","article-title":"Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT\/PDGFRA wild-type GISTs are rare events","volume":"62","author":"Huss","year":"2017","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.gassur.2025.102307_bib51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/ijc.25113","article-title":"Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors","volume":"127","author":"van Dongen","year":"2010","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.gassur.2025.102307_bib52","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1078-0432.CCR-16-1163","article-title":"PD-1\/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors","volume":"23","author":"Seifert","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gassur.2025.102307_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100910","article-title":"Single-cell transcriptional profiling uncovers the association between EOMES(+)CD8(+) T cells and acquired EGFR-TKI resistance","volume":"66","author":"Wang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.gassur.2025.102307_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun"},{"key":"10.1016\/j.gassur.2025.102307_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108276","article-title":"Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: progress, challenges, and trends","volume":"239","author":"Song","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gassur.2025.102307_bib56","article-title":"Beyond the driver mutation: immunotherapies in gastrointestinal stromal tumors","volume":"12","author":"Roulleaux","year":"2021","journal-title":"Front Immunol"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X2500366X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X2500366X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:33:10Z","timestamp":1773973990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X2500366X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1091255X2500366X"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2025.102307","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of immunotherapy in the treatment of tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2025.102307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of Society for Surgery of the Alimentary Tract.","name":"copyright","label":"Copyright"}],"article-number":"102307"}}